Cerulean's Dynamic Tumor Targeting™ Platform has advanced two NDCs into the clinic, which Cerulean is developing independently. Our platform has the potential to create additional NDCs, for development by Cerulean or in collaboration with other companies. Cerulean’s first platform-generated NDC clinical candidate, CRLX101, is being tested in combination with other therapies and has the potential to be combined with additional cancer treatments.

For information on partnering Cerulean's clinical candidates or its platform, please contact: BD@ceruleanrx.com.